FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical data trend for Marizyme's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Marizyme's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marizyme's FCF Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marizyme's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Marizyme's FCF Yield % falls into.
Marizyme FCF Yield % Calculation
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Marizyme's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marizyme FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Marizyme FCF Yield % Related Terms
Thank you for viewing the detailed overview of Marizyme's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRZM has been successfully added to your 